Identifying the functions of human immunodeficiency virus (HIV)-specific CD8 + T cells that are not merely modulated by the level of virus but clearly distinguish patients with immune control from those without such control is of paramount importance. Features of the HIV-specific CD8 + T-cell response in antiretroviral-treated patients (designated Rx <50) and untreated patients (long-term nonprogressors [LTNP]) matched for very low HIV RNA levels were comprehensively examined. The proliferative capacity of HIV-specific CD8 + T cells was not restored in Rx <50 to the level observed in LTNP, even though HIV-specific CD4 + T-cell proliferation in the two patient groups was comparable. This diminished HIV-specific CD8 + T-cell proliferation in Rx <50 was primarily due to a smaller fraction of antigen-specific cells recruited to divide and not to the numbers of divisions that proliferating cells had undergone. Exogenous interleukin-2 (IL-2) induced proliferating cells to divide further but did not rescue the majority of antigen-specific cells with defective proliferation. In addition, differences in HIV-specific CD8 + T-cell proliferation could not be attributed to differences in cellular subsets bearing a memory phenotype, IL-2 production, or PD-1 expression. Although polyfunctionality of HIV-specific CD8 + T cells in Rx <50 was not restored to the levels observed in LTNP despite prolonged suppression of HIV RNA levels, per-cell cytotoxic capacity was the functional feature that most clearly distinguished the cells of LTNP from those of Rx <50. Taken together, these data suggest that there are selective qualitative abnormalities within the HIV-specific CD8 + T-cell compartment that persist under conditions of low levels of antigen.
17 April 2018 in Proceedings of the National Academy of Sciences
The nervous system of the bowel regulates the inflammatory phenotype of tissue resident muscularis macrophages (MM), and in adult mice, enteric neurons are the main local source of colony stimulating factor 1 (CSF1), a protein required for MM survival. Surprisingly, we find that during development MM colonize the bowel before enteric neurons. This calls into question the requirement for neuron-derived CSF1 for MM colonization of the bowel. To determine if intestinal innervation is required for MM development, we analyzed MM of neonatal Ret−/− (Ret KO) mice that have no enteric nervous system in small bowel or colon. We found normal numbers of well-patterned MM in Ret KO bowel. Similarly, the abundance and distribution of MM in aganglionic human colon obtained from Hirschsprung disease patients was normal. We also identify endothelial cells and interstitial cells of Cajal as the main sources of CSF1 in the developing bowel. Additionally, MM from neonatal Ret KOs do not differ from controls in baseline activation status or cytokine-production in response to lipopolysaccharide. Unexpectedly, these data demonstrate that the enteric nervous system is dispensable for MM colonization and patterning in the bowel, and suggest that modulatory interactions between MM and the bowel nervous system are established postnatally. Significance Neurons and muscularis macrophages (MM) interact closely in the adult bowel and enteric neurons modulate the inflammatory response of neighboring MM. Enteric neurons also produce the essential macrophage survival factor colony stimulating factor 1. How MM–enteric neuron interactions are established during development has not been previously investigated. Surprisingly, we find that MM colonize fetal mouse bowel before enteric neurons. Furthermore, neonatal mouse and human bowel that is missing enteric neurons contains normal numbers of well-patterned, phenotypically intact MM. These data suggest that enteric neurons are not required for bowel colonization by MM and that modulatory neuro-immune circuits of the bowel mature postnatally and may be influenced by environmental factors like intestinal microbes or diet.
Key Points: Blockade of ST2 improves morbidity and mortality in murine FHL. Danger signals such as IL-33 may be required to amplify antigen-specific immune responses above the threshold for FHL disease in mice.